Evaxion A/S announced on July 25, 2025, that its two-year clinical efficacy data from the Phase 2 trial with lead compound EVX-01 has been accepted for oral presentation at the European Society for Medical Oncology (ESMO) Congress 2025. The congress will be held in Berlin, Germany, from October 17-21, 2025.
EVX-01 is a personalized cancer vaccine designed with Evaxion’s AI-Immunology platform, currently being evaluated as a treatment for advanced melanoma. The trial has previously yielded convincing interim one-year data, presented at the ESMO Congress in September 2024.
The one-year data demonstrated a 69% Overall Response Rate, reduction in tumor target lesions in 15 out of 16 patients, and a positive correlation between the AI-Immunology platform predictions and immune responses induced by individual neoantigens (p=0.00013). The upcoming presentation at ESMO is a significant opportunity to showcase these results to a large audience, including potential partners.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.